Volume 78, Issue 6 pp. 1279-1286
ORIGINAL ARTICLE

Formula modifications to the Crohn's disease exclusion diet do not impact therapy success in paediatric Crohn's disease

Emma Landorf

Corresponding Author

Emma Landorf

Department of Nutrition, Women's and Children's Hospital, Adelaide, South Australia, Australia

Correspondence Emma Landorf, Department of Nutrition, Women's and Children's Hospital, 72 King William Rd, North Adelaide, SA 5006, Australia.

Email: [email protected]

Search for more papers by this author
Paul Hammond

Paul Hammond

Department of Gastroenterology, Women's and Children's Hospital, Adelaide, South Australia, Australia

Search for more papers by this author
Rammy Abu-Assi

Rammy Abu-Assi

Department of Gastroenterology, Women's and Children's Hospital, Adelaide, South Australia, Australia

Search for more papers by this author
Samuel Ellison

Samuel Ellison

Department of Gastroenterology, Women's and Children's Hospital, Adelaide, South Australia, Australia

Search for more papers by this author
Terry Boyle

Terry Boyle

Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia

Search for more papers by this author
Annabel Comerford

Annabel Comerford

Department of Nutrition, Women's and Children's Hospital, Adelaide, South Australia, Australia

Search for more papers by this author
Richard Couper

Richard Couper

Department of Gastroenterology, Women's and Children's Hospital, Adelaide, South Australia, Australia

Search for more papers by this author
First published: 16 April 2024
Citations: 5

Abstract

Objectives

The Crohn's disease exclusion diet (CDED) + partial enteral nutrition (PEN) is an emerging diet used to induce clinical remission in children with active Crohn's disease (CD). This study aims to determine the effectiveness of using the CDED+PEN to induce clinical remission in an Australian group of children with active CD using different PEN formulas and incorporating patient dietary requirements.

Methods

We retrospectively collected data from children (both newly diagnosed and with existing CD while on therapy) with active CD (Paediatric Crohn's Disease Activity Index [PCDAI] ≥10) and biochemical evidence of active disease (elevated C-reactive protein [CRP], erythrocyte sedimentation rate [ESR] or faecal calprotectin [FC]) who completed at least phase 1 (6 weeks) of the CDED+PEN to induce clinical remission. Data were collected at baseline, Week 6 and Week 12. The primary endpoint was clinical remission at Week 6 defined as PCDAI < 10.

Results

Twenty-four children were included in phase 1 analysis (mean age 13.8 ± 3.2 years). Clinical remission at Week 6 was achieved in 17/24 (70.8%) patients. Mean PCDAI, CRP, ESR and FC decreased significantly after 6 weeks (p < 0.05). Formula type (cow's milk based, rice based, soy based) did not affect treatment efficacy. A greater than 50% decrease in FC was achieved in 14/21 (66.7%) patients who completed phase 1 and 12/14 (85.7%) patients who completed phase 2 of the CDED+PEN.

Conclusions

Formula modifications to the CDED+PEN do not impact the expected treatment efficacy in Australian children with active luminal CD.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author (E. L.) upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.